Medical devices, healthcare technology and the business of care
PMA approval · P190021

ReActiv8 Implantable Neurostimulation System

Mainstay Medical Limited · Decision date Jun 16, 2020

MEDTECHLEDGER EXPLANATIONP190021

What did the FDA approve?

FDA approved PMA P190021 for the ReActiv8 Implantable Neurostimulation System on June 16, 2020. The approval covers bilateral stimulation of the L2 medial branch of the dorsal ramus where it crosses the transverse process at L3, as an aid in managing intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed pain medications and physical therapy and are not candidates for spine surgery.

The device is classified as a totally implanted neuromuscular stimulator for lower back muscles, product code QLK, under the neurology specialty. The applicant is Mainstay Medical Limited. The approval statement describes the intended patient population and stimulation target but does not itself provide independent proof of safety or clinical effectiveness.

FDA approval order statement

Approval for the ReActiv8 System is indicated for bilateral stimulation of the L2 medial branch of the dorsal ramus as it crosses the transverse process at L3 as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy and are not candidates for spine surgery.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Jun 16, 2020

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P190021
Regulatory pathway
Premarket approval application
Product code
QLK
Decision code
APPR
Decision date
Jun 16, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief.

Product code
QLK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P190021 received

    Application receipt date recorded by FDA.

  2. P190021 · FDA decision

    APPR

  3. P190021/S012 · Related supplement

    ReActiv8 Implantable Neurostimulation System

Timeline entries are records held by MedtechLedger for P190021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190021

Product / regulatory recordCompanyPathwayDecision dateSource
Mainstay Medical LimitedPMA supplementOct 19, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Mainstay Medical Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Clonmel House Forster Way, Swords, Co Dublin, K67F2K3

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records